CHIX:GALDz (Switzerland)
Â
Registered Shares
CHF
167.5
-0.47 (-0.28%)
Jul 15
Business Description
Galderma Group AG
ISIN : CH1335392721
Share Class Description:
CHIX:GALDz: Registered SharesTotal Employee Number:
7,600Compare
Compare
Traded in other countries / regions
GALD.SwitzerlandGALDY.USAGALDz.UKGALDN.MexicoGALD.Austria1GALD.ItalyPY3.Germany IPO Date
2024-04-02Description
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.28 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.34 | |||||
Debt-to-EBITDA | 2.4 | |||||
Interest Coverage | 5 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 7.11 | |||||
Beneish M-Score | -2.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.5 | |||||
3-Year EBITDA Growth Rate | 16 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 30.98 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 17.74 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 13.22 | |||||
9-Day RSI | 29.64 | |||||
14-Day RSI | 39.7 | |||||
3-1 Month Momentum % | 10.05 | |||||
6-1 Month Momentum % | 8.74 | |||||
12-1 Month Momentum % | 37.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.19 | |||||
Quick Ratio | 0.93 | |||||
Cash Ratio | 0.38 | |||||
Days Inventory | 109.9 | |||||
Days Sales Outstanding | 60.04 | |||||
Days Payable | 163.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.21 | |||||
Dividend Payout Ratio | 0.07 | |||||
Forward Dividend Yield % | 0.21 | |||||
5-Year Yield-on-Cost % | 0.21 | |||||
3-Year Average Share Buyback Ratio | 0.4 | |||||
Shareholder Yield % | 1.63 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.86 | |||||
Operating Margin % | 16.71 | |||||
Net Margin % | 11.66 | |||||
EBITDA Margin % | 21.66 | |||||
FCF Margin % | 19.67 | |||||
OCF Margin % | 22.61 | |||||
ROE % | 7.48 | |||||
ROA % | 4.55 | |||||
ROIC % | 6.85 | |||||
ROC (Joel Greenblatt) % | 118.49 | |||||
ROCE % | 7.01 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 80.82 | |||||
Forward PE Ratio | 45.26 | |||||
PE Ratio without NRI | 75.36 | |||||
Price-to-Owner-Earnings | 51.2 | |||||
PS Ratio | 9.4 | |||||
PB Ratio | 6.05 | |||||
Price-to-Free-Cash-Flow | 47.8 | |||||
Price-to-Operating-Cash-Flow | 41.58 | |||||
EV-to-EBIT | 62.24 | |||||
EV-to-Forward-EBIT | 43.78 | |||||
EV-to-EBITDA | 44.53 | |||||
EV-to-Forward-EBITDA | 33.81 | |||||
EV-to-Revenue | 9.64 | |||||
EV-to-Forward-Revenue | 8.01 | |||||
EV-to-FCF | 50.81 | |||||
Earnings Yield (Greenblatt) % | 1.61 | |||||
FCF Yield % | 2.13 |
GF Valueâ„¢
Galderma Group AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Galderma Group AG Stock Events
| Event | Date | Price (CHF) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-07-24 | In 8 days | ||
| Second quarter earnings results for 2026 | 2026-07-24 | In 8 days | ||
| CHF 0.350000 Cash Dividend | 2026-04-24 | 159.95 (+0.35%) | ||
| General meeting for 2026 | 2026-04-22 15:00 | 152.60 (-1.26%) | ||
| Annual report for 2025 | 2026-03-05 | 145.10 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 145.10 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-07-24 | 123.80 (-0.36%) | ||
| Second quarter earnings results for 2025 | 2025-07-24 | 123.80 (-0.36%) | ||
| CHF 0.150000 Cash Dividend | 2025-04-25 | 90.00 (+3.54%) | ||
| General meeting for 2025 | 2025-04-23 | 77.45 (-0.71%) |
Show
Entries
Press Release
Articles on Galderma Group AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers